- Market cap
- Revenue
- Net income
- Cash on hand
- Gross margin
- Net margin
- EPS
- P/E ratio
https://www.sec.gov/Archives/edgar/data/1133818/000166357726000240/bpth_supp1.htm The post SEC Form: 253G2 appeared first on BioPath Holdings.
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001133818/000166357726000218/bpth_8k071626.htm The post SEC Form: 8-K: Current Report 3.02 – Unregistered Sales of Equity Securities 5.03 – Amendments to Articles of Incorporation or Bylaws Change in Fiscal Year 7.01 – Regulation FD Disclosure 8.01 – Other Events (The registrant can use this Item to report events that are not specifically called for by Form 8-K, that the registrant considers to be of importance to security holders.) 9.01 – Financial Statements and Exhibits appeared first on BioPath Holdings.
https://www.einpresswire.com/article/912696538/bio-path-announces-repositioning-to-support-growth-adds-scientific-advisors-engages-bankers-cancels-reverse-split The post BIO-PATH ANNOUNCES REPOSITIONING TO SUPPORT GROWTH, ADDS SCIENTIFIC ADVISORS, ENGAGES BANKERS, CANCELS REVERSE SPLIT appeared first on BioPath Holdings.
Biomedical research professional with expertise in large research collaborations, consortia, R&D alliances, IP asset portfolio management, medical product development partnerships, venture development, and seed funding. Over 25 years at the academic heath system-industry interface, with a record of operational excellence and closed deals. I specialize in new collaboration models and deal structures for scaling clinical […] The post Dr. Rick Silva appeared first on BioPath Holdings.
Wendy M. Charles, PhD, MS, CIP, CCRP is a clinical scientist, digital health leader, and educator with more than 25 years of experience spanning clinical research operations, regulatory compliance, health information technology, and emerging technologies in life sciences. She holds a PhD in Clinical Science with a specialty in Health Information Technology from the University of Colorado […] The post Dr. Wendy Charles, PhD, CIP, CCRP, CBP appeared first on BioPath Holdings.
Vik Grover was named Chairman and CEO of Bio-Path Holdings in October 2025 to effect a turnaround of the public company and reengage the Company’s Phase 1 and Phase 2 trials. He is currently CEO of Himalaya Technologies, Inc., owner and operator of a crypto social network, CEO of Everest Networks, Inc., owner and operator […] The post Vikram Grover appeared first on BioPath Holdings.
https://www.sec.gov/Archives/edgar/data/1133818/000166357726000075/xsl1-A_X01/primary_doc.xml The post SEC Form: 1-A: Offering Statement [Regulation A] appeared first on BioPath Holdings.
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001133818/000166357726000064/bpth_8k031926.htm The post SEC Form: 8-K – 5.03 – Amendments to Articles of Incorporation or Bylaws Change in Fiscal Year – 8.01 – Other Events -9.01 – Financial Statements and Exhibits appeared first on BioPath Holdings.
https://www.sec.gov/Archives/edgar/data/0001133818/000166357726000050/xsl1-Z_X01/primary_doc.xml The post SEC Form 1-Z: Exit Report appeared first on BioPath Holdings.
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001133818/000166357726000046/bpth_8k022426.htm The post SEC Form-8K: Current Report 5.01 – Changes in Control of Registrant; 5.03 – Amendments to Articles of Incorporation; 7.01 – Regulation FD Disclosure; 8.01 – Other Events appeared first on BioPath Holdings.